---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265702"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:13:16.338478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics Q3 2025: Net loss $47.7M, nomlabofusp shows 100% FXN level in OL study

## Summary
- Net loss for Q3 2025 was $47.7M ($0.61 per share) vs $15.5M in Q3 2024, with R&D expenses up to $44.9M.
- 100% of participants (n=10) achieved skin FXN levels similar to asymptomatic carriers after 6 months of daily nomlabofusp in open-label study.
- Anaphylaxis occurred in 7 of 65 total participants; new modified starting dose regimen implemented to mitigate risk, agreed with FDA.
- BLA submission seeking accelerated approval targeted for Q2 2026, with $175.4M cash runway into Q4 2026.
- Consistent directional improvement across mFARS, FARS-ADL, 9-HPT, and MFIS after 1 year versus worsening in FACOMS reference.

## SEC filing metadata
- accession: 0001193125-25-265702
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/0001193125-25-265702-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000119312525265702/lrmr-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265702
- JSON: https://secwatch.observer/filing/0001193125-25-265702.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265702.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.